GAM
IONS icon

Groupama Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Groupama Asset Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.2M Buy
937,083
+112,543
+14% +$8.47M 0.95% 29
2026
Q1 		$61.9M Buy
824,540
+57,651
+8% +$4.55M 0.9% 33
2025
Q4 		$60.7M Buy
766,889
+205,112
+37% +$15.4M 0.89% 29
2025
Q3 		$37.4M Sell
561,777
-99,180
-15% -$4.84M 0.55% 42
2025
Q2 		$26.8M Buy
660,957
+91,746
+16% +$3M 0.44% 49
2025
Q1 		$18.2M Buy
569,211
+52,020
+10% +$1.7M 0.36% 58
2024
Q4 		$18.6M Buy
517,191
+101,131
+24% +$3.78M 0.38% 56
2024
Q3 		$13.8M Buy
416,060
+36,084
+9% +$1.68M 0.36% 57
2024
Q2 		$18.1M Buy
379,976
+122,108
+47% +$5.01M 0.25% 72
2024
Q1 		$17M Sell
257,868
-99,168
-28% -$4.73M 0.31% 67
2023
Q4 		$18.1M Buy
+357,036
New +$17.1M 0.47% 46

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Groupama Asset Management's IONS Position: Q2 2026 in Review

Groupama Asset Management increased its Ionis Pharmaceuticals (IONS) stake by 14% in Q2 2026, buying an estimated $8.47M and bringing the position to 937,083 shares worth $75.2M. The position accounts for 0.95% of the portfolio, ranked #29.

Groupama Asset Management first reported a position in IONS in Q4 2023 and has held it in 11 quarters since. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Groupama Asset Management held 937,083 shares of Ionis Pharmaceuticals worth $75.2M as of Q2 2026.
  • Groupama Asset Management bought 112,543 Ionis Pharmaceuticals shares in Q2 2026, an estimated $8.47M.
  • Ionis Pharmaceuticals made up 0.95% of Groupama Asset Management's portfolio in Q2 2026, its #29 holding.
  • Groupama Asset Management first reported a position in Ionis Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Groupama Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.